PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 11844153-5 2001 Finally, potential therapeutic strategies are discussed to modify NF-kappaB activity with certain immunosuppression medications, including cyclosporine, tacrolimus, and glucocorticoids. Tacrolimus 153-163 nuclear factor kappa B subunit 1 Homo sapiens 66-75 10543746-6 1999 On the other hand, FK506, which is also a macrolide derivative, inhibited transcriptional activation of both NF-kappaB and NFAT more strongly than EM did. Tacrolimus 19-24 nuclear factor kappa B subunit 1 Homo sapiens 109-118 10688206-2 2000 FK506 and cyclosporin are immunosuppressants which block three antigen-receptor signalling pathways (NFAT, NFkappaB and JNK), through inhibition of calcineurin, and inhibit mature lymphocyte proliferation to antigen. Tacrolimus 0-5 nuclear factor kappa B subunit 1 Homo sapiens 107-115 10796896-8 2000 Increased staining intensity and frequency of NF-kappaB-positive cells were similarly observed in HCV-positive allografts obtained from patients under tacrolimus- compared with cyclosporine-based immunosuppression. Tacrolimus 151-161 nuclear factor kappa B subunit 1 Homo sapiens 49-55 10543746-8 1999 Expression of calcineurin did not render transactivation of NF-kappaB in T cells more resistant to EM, while the inhibitory effect of FK506 on transactivation of NF-kappaB was attenuated. Tacrolimus 134-139 nuclear factor kappa B subunit 1 Homo sapiens 162-171 9824778-9 1998 Cyclosporine and tacrolimus prevent NF-kappa B activation by inhibiting the action of calcineurin, a phosphatase that indirectly induces I kappa B degradation. Tacrolimus 17-27 nuclear factor kappa B subunit 1 Homo sapiens 36-46 10592469-9 1999 IL-8 production was significantly inhibited by N-acetyl-L-cysteine, FK506 and MG-132, inhibitors of NF-kappaB activation and translocation. Tacrolimus 68-73 nuclear factor kappa B subunit 1 Homo sapiens 100-109 9247567-2 1997 Inhibition of T cell activation by the immunosuppressants cyclosporin A (CsA) and FK506 exerts a suppressive effect on the induction of these NF-kappa B-controlled cytokine promoters. Tacrolimus 82-87 nuclear factor kappa B subunit 1 Homo sapiens 142-152 8647935-0 1996 Immunosuppressant FK506 induces interleukin-6 production through the activation of transcription factor nuclear factor (NF)-kappa(B). Tacrolimus 18-23 nuclear factor kappa B subunit 1 Homo sapiens 104-131 8647935-2 1996 FK506 is a powerful immunosuppressive drug currently in use that inhibits the activation of several transcription factors (nuclear factor (NF)-AT and NF-kappaB) critical for T cell activation. Tacrolimus 0-5 nuclear factor kappa B subunit 1 Homo sapiens 150-159 8647935-3 1996 We show here that, contrary to the situation in T cells, FK506 activates transcription factor NF-kappaB in nonlymphoid cells such as fibroblasts and renal mesangial cells. Tacrolimus 57-62 nuclear factor kappa B subunit 1 Homo sapiens 94-103 8647935-4 1996 We further show that FK506 induces NF-kappaB-regulated IL-6 production in vitro and in vivo, in particular in kidney. Tacrolimus 21-26 nuclear factor kappa B subunit 1 Homo sapiens 35-44 8647935-7 1996 These results thus suggest a causal relationship between FK506-induced NF-kappaB activation/IL-6 production and some of FK506-induced renal abnormalities. Tacrolimus 57-62 nuclear factor kappa B subunit 1 Homo sapiens 71-80 8647935-7 1996 These results thus suggest a causal relationship between FK506-induced NF-kappaB activation/IL-6 production and some of FK506-induced renal abnormalities. Tacrolimus 120-125 nuclear factor kappa B subunit 1 Homo sapiens 71-80 7693698-4 1993 Both p50 and p54 bind an FK506 affinity resin at 0.5 M KCl, but only p50 binds efficiently in low salt conditions. Tacrolimus 25-30 nuclear factor kappa B subunit 1 Homo sapiens 5-8 7510691-6 1994 In contrast, FK506 or EGTA (Ca2+ chelator) similarly affected the formation of kappa B-like site binding complexes, which were not recognized by any antibodies against the human Rel family proteins (c-Rel, p65, p50, and p49). Tacrolimus 13-18 nuclear factor kappa B subunit 1 Homo sapiens 211-214 7510691-7 1994 Furthermore, we confirmed the previous report that FK506 suppressed the PMA/ionomycin-induced activation through authentic kappa B site of immunoglobulin (Ig) gene, to which NF-kappa B binding was also decreased by FK506, indicating that both IL-8 kappa B-like site and Ig kappa B site are FK506-sensitive in spite of the difference of binding factors. Tacrolimus 51-56 nuclear factor kappa B subunit 1 Homo sapiens 174-184 7510691-7 1994 Furthermore, we confirmed the previous report that FK506 suppressed the PMA/ionomycin-induced activation through authentic kappa B site of immunoglobulin (Ig) gene, to which NF-kappa B binding was also decreased by FK506, indicating that both IL-8 kappa B-like site and Ig kappa B site are FK506-sensitive in spite of the difference of binding factors. Tacrolimus 215-220 nuclear factor kappa B subunit 1 Homo sapiens 174-184 7510691-7 1994 Furthermore, we confirmed the previous report that FK506 suppressed the PMA/ionomycin-induced activation through authentic kappa B site of immunoglobulin (Ig) gene, to which NF-kappa B binding was also decreased by FK506, indicating that both IL-8 kappa B-like site and Ig kappa B site are FK506-sensitive in spite of the difference of binding factors. Tacrolimus 215-220 nuclear factor kappa B subunit 1 Homo sapiens 174-184 1721310-0 1991 Activation of transcription factor NF kappa B in Jurkat cells is inhibited selectively by FK 506 in a signal-dependent manner. Tacrolimus 90-96 nuclear factor kappa B subunit 1 Homo sapiens 35-45 34575860-4 2021 We hypothesized that CsA and Tac induce functional defects and activate an inflammatory cascade via NF-kappaB signaling in ECFCs. Tacrolimus 29-32 nuclear factor kappa B subunit 1 Homo sapiens 100-109 34575860-12 2021 Pharmacological inhibition of NF-kappaB by parthenolide diminished CsA- and Tac-mediated proinflammatory effects. Tacrolimus 76-79 nuclear factor kappa B subunit 1 Homo sapiens 30-39 23140765-0 2012 Differential regulation of nuclear factor-kappa B subunits on epidermal keratinocytes by ultraviolet B and tacrolimus. Tacrolimus 107-117 nuclear factor kappa B subunit 1 Homo sapiens 27-49 29520229-0 2018 Tacrolimus Reverses UVB Irradiation-Induced Epidermal Langerhans Cell Reduction by Inhibiting TNF-alpha Secretion in Keratinocytes via Regulation of NF-kappaB/p65. Tacrolimus 0-10 nuclear factor kappa B subunit 1 Homo sapiens 149-158 29520229-11 2018 Tacrolimus significantly inhibited UVB irradiation-induced tumor necrosis factor-alpha (TNF-alpha) and nuclear factor kappa B (NF-kappaB)/p65 mRNA and protein expression in HaCaT cells. Tacrolimus 0-10 nuclear factor kappa B subunit 1 Homo sapiens 103-125 29520229-11 2018 Tacrolimus significantly inhibited UVB irradiation-induced tumor necrosis factor-alpha (TNF-alpha) and nuclear factor kappa B (NF-kappaB)/p65 mRNA and protein expression in HaCaT cells. Tacrolimus 0-10 nuclear factor kappa B subunit 1 Homo sapiens 127-136 29520229-14 2018 Conclusion: Topical tacrolimus 0.03% could reverse UVB irradiation-induced epidermal LC reduction by inhibiting TNF-alpha secretion in keratinocytes via regulation of NF-kappaB/p65. Tacrolimus 20-30 nuclear factor kappa B subunit 1 Homo sapiens 167-176 22885734-11 2012 Nuclear translocation of p50 and p65 NF-kappaB in response to IL-1beta was decreased by tacrolimus. Tacrolimus 88-98 nuclear factor kappa B subunit 1 Homo sapiens 25-28 22885734-11 2012 Nuclear translocation of p50 and p65 NF-kappaB in response to IL-1beta was decreased by tacrolimus. Tacrolimus 88-98 nuclear factor kappa B subunit 1 Homo sapiens 37-46 32664235-10 2020 Tacrolimus prevented the increased expression of PLA2R, NFKB1 and IRF4 induced by TWEAK in cultured podocytes. Tacrolimus 0-10 nuclear factor kappa B subunit 1 Homo sapiens 56-61 25043904-8 2014 Accordingly, the inhibition of CaN by FK506 increased NF-kappaB activity in dorsal hippocampus. Tacrolimus 38-43 nuclear factor kappa B subunit 1 Homo sapiens 54-63 25043904-9 2014 The administration of the NF-kappaB signaling pathway inhibitor sulfasalazine (SSZ) impeded the enhancing effect of FK506. Tacrolimus 116-121 nuclear factor kappa B subunit 1 Homo sapiens 26-35 25043904-12 2014 The coadministration of SSZ and FK506 blocked the enhancement effect in reconsolidation, suggesting that this facilitation is also dependent on the NF-kappaB signaling pathway. Tacrolimus 32-37 nuclear factor kappa B subunit 1 Homo sapiens 148-157 23573283-0 2013 Tacrolimus inhibits NF-kappaB activation in peripheral human T cells. Tacrolimus 0-10 nuclear factor kappa B subunit 1 Homo sapiens 20-29 22885734-6 2012 The effects of tacrolimus on nuclear translocation of nuclear factor-kappaB (NF-kappaB) were also examined. Tacrolimus 15-25 nuclear factor kappa B subunit 1 Homo sapiens 54-75 23140765-2 2012 Recently, we have shown that direct regulation of NF-kappaB/p65 subunit may account for tacrolimus ointment"s remarkable clinical efficacy on treating inflammatory dermatoses. Tacrolimus 88-98 nuclear factor kappa B subunit 1 Homo sapiens 50-59 23140765-10 2012 Furthermore, treatment with tacrolimus didn"t affect the nuclear activation and translocation of NF-kappaB/p50, while the UVB induced NF-kappaB/p65 nuclear expression was suppressed by tacrolimus. Tacrolimus 185-195 nuclear factor kappa B subunit 1 Homo sapiens 134-143 23140765-12 2012 The clinical efficacy of tacrolimus may be attributed to its specific regulatory effect on NF-kappaB/p65 but not NF-kappaB/p50 of the NF-kappaB pathway. Tacrolimus 25-35 nuclear factor kappa B subunit 1 Homo sapiens 91-100 15851377-12 2005 NFkappaB activity in TNF-alpha-stimulated synovial cells was suppressed more profoundly by FK506 plus TP (10 ng/ml) than by TP (10 ng/ml) alone. Tacrolimus 91-96 nuclear factor kappa B subunit 1 Homo sapiens 0-8 19084239-2 2009 Previously, intestines from donors receiving Tacrolimus revealed improved morphology and abrogated nuclear factor kappa B (NF-kappaB) activation. Tacrolimus 45-55 nuclear factor kappa B subunit 1 Homo sapiens 99-121 19084239-2 2009 Previously, intestines from donors receiving Tacrolimus revealed improved morphology and abrogated nuclear factor kappa B (NF-kappaB) activation. Tacrolimus 45-55 nuclear factor kappa B subunit 1 Homo sapiens 123-132 19473564-10 2009 Furthermore, tacrolimus also decreased the IL-1Beta-induced DNA binding activity of p65, a subunit of NF-KappaB, in the presence of 10-9 M of Dex. Tacrolimus 13-23 nuclear factor kappa B subunit 1 Homo sapiens 102-111 18320068-0 2008 FK506 binding protein mediates glioma cell growth and sensitivity to rapamycin treatment by regulating NF-kappaB signaling pathway. Tacrolimus 0-5 nuclear factor kappa B subunit 1 Homo sapiens 103-112 17347151-9 2007 Importantly, both CyA and FK506 down-regulated LPS-induced IL-12p40 transcription by inhibiting CaM/CaMK-II-activated PI3K and their downstream transcription factors NFkappaB and AP-1 independent of the JNK pathway. Tacrolimus 26-31 nuclear factor kappa B subunit 1 Homo sapiens 166-174 17038582-4 2007 Here, we show that treatment of T cells with cyclosporin A, FK506, and dexamethasone, which are known to inhibit calcineurin and NF-kappaB, respectively, but not rapamycin, the inhibitor of mammalian target of rapamycin, selectively prevented TCR/CD3 relocalization into the IS, while relocalization of adhesion and cytoskeletal proteins as well as T cell/APC conjugate formation remained unaltered. Tacrolimus 60-65 nuclear factor kappa B subunit 1 Homo sapiens 129-138 15851377-14 2005 CONCLUSION: FK506 enhanced TP-mediated down-regulation of COX-2 and iNOS as well as their products PGE subset2 and NO in human TNF-alpha-stimulated RASF by more profoundly suppressing the activity of NFkappaB. Tacrolimus 12-17 nuclear factor kappa B subunit 1 Homo sapiens 200-208 15489928-2 2004 METHODS: Immunohistochemistry has been employed to study the expression of NF-kappaB in normal skin and lesional AD skin before and after using topical tacrolimus ointment. Tacrolimus 152-162 nuclear factor kappa B subunit 1 Homo sapiens 75-84 15489928-5 2004 After using topical tacrolimus ointment for three weeks , nuclear NF-kappaBp50 expressed on basal and suprabasal keratinocytes were lost and NF-kappaBp50 was expressed sparsely on basal keratinocytes cytoplasm or nuclear. Tacrolimus 20-30 nuclear factor kappa B subunit 1 Homo sapiens 66-78 15489928-5 2004 After using topical tacrolimus ointment for three weeks , nuclear NF-kappaBp50 expressed on basal and suprabasal keratinocytes were lost and NF-kappaBp50 was expressed sparsely on basal keratinocytes cytoplasm or nuclear. Tacrolimus 20-30 nuclear factor kappa B subunit 1 Homo sapiens 141-153 15489928-8 2004 Topical tacrolimus may directly or indirectly inhibit NF-kappaB nuclear expression in keratinocytes and inhibit skin innate immuno-inflammatory response in atopic dermatitis that related to NF-kappaB. Tacrolimus 8-18 nuclear factor kappa B subunit 1 Homo sapiens 54-63 15489928-8 2004 Topical tacrolimus may directly or indirectly inhibit NF-kappaB nuclear expression in keratinocytes and inhibit skin innate immuno-inflammatory response in atopic dermatitis that related to NF-kappaB. Tacrolimus 8-18 nuclear factor kappa B subunit 1 Homo sapiens 190-199 15108766-0 2004 Activation of nuclear factor-kappa B and macrophage invasion in cyclosporin A-and tacrolimus-treated renal transplants. Tacrolimus 82-92 nuclear factor kappa B subunit 1 Homo sapiens 14-36 15108766-1 2004 This retrospective study was designed to compare the efficacy of cyclosporin A (CyA) and tacrolimus (FK506) on chronic rejection (CR) associated with nuclear factor-kappa B (NF-kappaB) activation and macrophage invasion. Tacrolimus 89-99 nuclear factor kappa B subunit 1 Homo sapiens 150-172 15108766-1 2004 This retrospective study was designed to compare the efficacy of cyclosporin A (CyA) and tacrolimus (FK506) on chronic rejection (CR) associated with nuclear factor-kappa B (NF-kappaB) activation and macrophage invasion. Tacrolimus 89-99 nuclear factor kappa B subunit 1 Homo sapiens 174-183 15108766-1 2004 This retrospective study was designed to compare the efficacy of cyclosporin A (CyA) and tacrolimus (FK506) on chronic rejection (CR) associated with nuclear factor-kappa B (NF-kappaB) activation and macrophage invasion. Tacrolimus 101-106 nuclear factor kappa B subunit 1 Homo sapiens 150-172 15108766-1 2004 This retrospective study was designed to compare the efficacy of cyclosporin A (CyA) and tacrolimus (FK506) on chronic rejection (CR) associated with nuclear factor-kappa B (NF-kappaB) activation and macrophage invasion. Tacrolimus 101-106 nuclear factor kappa B subunit 1 Homo sapiens 174-183 12767900-8 2003 Activation of NF-kappa B occurred in response to IFN-gamma, and which was markedly inhibited by either CsA or FK506. Tacrolimus 110-115 nuclear factor kappa B subunit 1 Homo sapiens 14-24 12732617-4 2003 Chemical cross-linking and coimmunoprecipitation show that NFkappaB/Rel factor-bound IkappaBbeta forms a ternary complex with Cn under in vitro and in vivo conditions that was sensitive to FK506. Tacrolimus 189-194 nuclear factor kappa B subunit 1 Homo sapiens 59-67 12621554-10 2003 NF-kappa B activity in TNF alpha-stimulated synovial cells was suppressed more profoundly by FK506 plus TP (10 microg/L) treatment than those with TP (10 microg/L) alone. Tacrolimus 93-98 nuclear factor kappa B subunit 1 Homo sapiens 0-10 12621554-12 2003 In conclusion, FK506 enhanced TP-mediated down-regulation of COX-2, iNOS and their inducing products PGE2, NO in human RASF by suppressing the activity of NF-kappa B. Tacrolimus 15-20 nuclear factor kappa B subunit 1 Homo sapiens 155-165